Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TFT conditioning for 2nd allogeneic PBSCT in AML relapse after prior HSCT
DRKS00005126Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Mar 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa, fludarabine and treosulfan in acute myeloid leukemia (AML), sponsored by Universitätsklinikum Freiburg. Started Mar 2014; status: completed.
02
Drugs
thiotepafludarabinetreosulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00005126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005126.